FRITSCH EDWARD F,HACOHEN NIR,ROONEY MICHAEL STEVEN,SHUKLA SACHET ASHOK,WU CATHERINE J,BACHIREDDY PAVAN,SUN JING
申请号：
IN201717042732
公开号：
IN201717042732A
申请日:
2017.11.29
申请国别(地区):
IN
年份:
2018
代理人:
摘要：
Disclosed herein in one aspect is a pharmaceutical composition comprising a plurality of neoantigenic peptides and a pharmaceutically acceptable carrier each neoantigenic peptide comprising a tumor specific neoepitope capable of binding to an HLA protein in a subject each tumor specific neoepitope comprising a tumor specific mutation present in a tumor wherein (a) the composition comprises neoantigenic peptides comprising tumor specific mutations present in at least 1% of subjects in a population of subjects suffering from cancer； (b) the composition comprises neoantigenic peptides comprising tumor specific neoepitopes which bind to HLA proteins present in at least 5% of subjects in the population； and (c) the composition comprises at least one neoantigenic peptide capable of eliciting an immune response against a tumor present in at least 5% of the subjects in the population of subjects suffering from cancer.
